Therapeutics News and Research

RSS
VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

1 Apr 2011
Akela reports net income of $1.5 million for three months ended December 31, 2010

Akela reports net income of $1.5 million for three months ended December 31, 2010

1 Apr 2011
Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

1 Apr 2011
FDA grants Nile Fast Track designation for cenderitide post-acute development program

FDA grants Nile Fast Track designation for cenderitide post-acute development program

31 Mar 2011
Protox reports net loss of $4.5 million for year ended December 31, 2010

Protox reports net loss of $4.5 million for year ended December 31, 2010

31 Mar 2011
RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals to acquire Apthera

31 Mar 2011
Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

Pacira reports net loss of $7.0 million for quarter ended December 31, 2010

31 Mar 2011
Cancer Commons researchers publish MDMM paper in PLoS ONE journal

Cancer Commons researchers publish MDMM paper in PLoS ONE journal

31 Mar 2011
Cellectis 2010 total operating revenues increase 55% to EUR 15.8M

Cellectis 2010 total operating revenues increase 55% to EUR 15.8M

31 Mar 2011
Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

Rexahn's RX-5902 pre-clinical data against cancer to be presented at AACR Annual Meeting

31 Mar 2011
Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

31 Mar 2011
EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

30 Mar 2011
SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

30 Mar 2011
Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

30 Mar 2011
Positive results from Vertex VX-770 Phase 3 trial against CF

Positive results from Vertex VX-770 Phase 3 trial against CF

30 Mar 2011
Researchers develop new drug for multiple cancer treatment

Researchers develop new drug for multiple cancer treatment

30 Mar 2011
EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

30 Mar 2011
Osseon launches Osseoflex BT Steerable Bone Tamp for physicians

Osseon launches Osseoflex BT Steerable Bone Tamp for physicians

30 Mar 2011
SRI International, CDD receive NIAID grant to develop TB information repository

SRI International, CDD receive NIAID grant to develop TB information repository

29 Mar 2011
PPD introduces new mobile application for clinical trial searches

PPD introduces new mobile application for clinical trial searches

29 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback